Generic Faculty Photo

Lokesh Nagaprashantha, Ph.D.

  • Staff Scientist, Department of Molecular Medicine

Lokesh Nagaprashantha, Ph.D.

Research Focus :
  • Translational Cancer Drug and/Combinations Development
  • Cancer Project Management
  • Drug and Radiation Resistance
  • 2017-present, Staff Scientist, Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA.
  • 2012-2013, Postdoctoral Fellow, Department of Diabetes and Metabolic Diseases, Beckman Research Institute of City of Hope, Duarte, CA.
  • 2011-2012, Postdoctoral Research, Department of Cancer Biology at University of North Texas Health Science Center (UNTHSC) in collaboration with Sharad Singhal, Ph.D., at City of Hope and Laszlo Prokai, Ph.D., at UNTHSC.
  • Molecular Medicine
  • Diabetes and Metabolic Diseases


  • University of North Carolina at Chapel Hill, NC, USA, Business/Management Certificate, UNC Business Essentials Certificate Program, UNCBE.
  • University of North Texas Health Science Center, Fort Worth, TX, USA, Ph.D. (Distinction), Cancer Biology
  • New York Medical College, Valhalla, NY, USA, M.S., Biochemistry and Molecular Biology
  • Rajiv Gandhi University of Health Sciences, Bangalore, Karnataka, India, M.B.B.S., (Medical Doctor), Medicine and Surgery.
Dr. Nagaprashantha’s multidisciplinary expertise, ability to provide novel insights, develop relevant research strategy and contribute expert inputs during conduct of studies is considered a significant strength for developmental cancer therapy projects. Dr. Nagaprashantha mentors internal and collaborating researchers on clinical translational scope, significance and strategies to be employed towards productive realization of project goals while serving as a key liaison on clinical and basic science parameters in translational oncology for team members.
Our laboratory is interested in understanding the fundamental mechanisms of carcinogenesis, metastases, drug-resistance and radiation-resistance at signaling network and pathway levels to elucidate the differential regulation of cellular signaling mechanisms. These strategies have been successfully employed to identify, characterize and perform multiple translational studies in novel molecular medicine projects. We have worked extensively on developmental therapies in lung cancer, breast cancer, renal cancer, prostate cancer, pancreatic cancer, neuroblastoma and melanomas.
We employ a sound combination of genetic, molecular biology and proteomic investigations in addressing essential and clinical-translational parameters to expand the understanding of the scientific basis for novel developmental agents and/combinations.
Contribution to Science
  1. Expert opinion on molecular profile of cancers responsible for therapeutic challenges and providing insights on novel combination therapies for respective cancers.
    a. Lokesh Dalasanur Nagaprashantha (2012-Current, Invited Monograph) Combinatorial Cancer Therapy.  Encyclopedia of Cancer (A Reference for both Researchers and Public), ID 7158.  
    b. Singhal S.S., Nagaprashantha L., Singhal P., Singhal S., Singhal J., Awasthi S., Horne D. (2017) RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma. Pharm Res., [Epub ahead of print].
    c. Nagaprashantha, L.D., Vatsyayan, R., Lelsani, P.C., Awasthi, S., Singhal, S.S. (2011) The sensors and regulators of cell-matrix surveillance in anoikis resistance of tumors. Int J Cancer 128: 743-752.
    d. Nagaprashantha L., Vartak N., Awasthi S, Awasthi S., Singhal S.S. (2012) Novel anticancer compounds for developing combinatorial therapies to target anoikis-resistant tumors.  Pharm Res 29: 621-636.
  2. Signaling network analyses to assess specific pathways and networks associated with carcinogenesis. These studies focus on proteomic analyses of cancer cells, use of relevant software like Ingenuity Pathway Analyses (IPA) and extensive search of literature to derive translationally significant inferences.
    a. Nagaprashantha, L., Talamantes, T., Singhal, J., Guo, J., Vatsyayan, R., Rauniyar, N., Awasthi, S., Singhal, S.S., Prokai, L. (2013) Proteomic analysis of signaling networks regulation in renal cell carcinoma with differential hypoxia-inducible factor-2α expression.  PLoS ONE 8(8): e71654.
  3. Translational developmental cancer therapy projects focused on antisense, antibodies, novel lead compounds and phytochemicals for broader targeting of (i) Carcinogenesis, (ii) Metastases mechanisms, and cancer risk factors like (iii) Hyperglycemia and Hypercholesterolemia.
    a. Nagaprashantha, L.D., Vatsyayan, R., Singhal, J., Lelsani, P.C., Prokai, L., Awasthi, S., Singhal, S.S. (2011) 2'-Hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant Renal Cell Carcinoma. Carcinogenesis 32: 568-575.
    b. Singhal J, Nagaprashantha, L.D., Vatsyayan, R., Awasthi S., Singhal S.S. (2011) RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome.  PLoS ONE 6(9): e24688.
    c. Singhal J, Nagaprashantha L, Vatsyayan R, Ashutosh, Awasthi, S., Singhal SS.  (2012) Didymin induces apoptosis by inhibiting N-Myc and up-regulating RKIP in neuroblastoma. Cancer Prev Res 5: 473-483.
    d. Singhal, S.S., Figarola, J., Singhal, J., Leake, K., Nagaprashantha, L., Lincoln, C., Gigiu, G., Horn, D., Jove, R., Awasthi, S., Rahbar, S. (2012) 1,3-bis(3,5-dichlorophenyl) urea compound ‘COH-SR4’ inhibits proliferation and activates apoptosis in melanoma.  Biochem Pharmacol 84: 1419-1427.
    e. Singhal S.S., Figarola J., Singhal J., Nagaprashantha L., Berz, D., Rahbar S.,  Awasthi S. (2013) Novel compound 1, 3-bis (3, 5-dichlorophenyl) urea inhibits lung cancer progression. Biochem Pharmacol 86: 1664-1672.
  4. Targeting specific clinical-translational molecular profile of tumors by devising novel, stage-specific mono and combinatorial translational therapies for aggressive and therapy resistant cancers.
    a. Nagaprashantha, L.D., Vatsyayan, R., Singhal, J., Fast, S., Roby, R., Awasthi, S., Singhal, S.S. (2011) Anticancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. Biochem Pharmacol 82: 1100-1109.
    b. Leake, K., Singhal, J., Nagaprashantha, L.D., Awasthi, S., Singhal, S.S.  (2012) RLIP76 regulates PI3K/Akt signaling and chemo-radio-therapy resistance in pancreatic cancer. PLoS ONE 7(4): e34582.  
    c. Vatsyayan R, Singhal, J., Nagaprashantha L., Awasthi, S., Singhal S.S. (2013) Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.  Mol Carcinogenesis 52: 39-48.
    d. Singhal J., Yadav S., Nagaprashantha L., Vatsyayan R., Singhal S.S, and Awasthi S. (2011) Targeting p53 null neuroblastomas through RLIP76.  Cancer Prev Res 4: 879-889.
Back To Top